Stelo is primarily intended for patients with prediabetes or Type 2 diabetes ... It was the first over-the-counter continuous glucose monitor to be cleared for use, though Dexcom's competitor ...

Abbott Lingo biowearable made its debut in the UK and expanded to the US, and Dexcom launched its Stelo CGM, targeting individuals with pre-diabetes. But perhaps the biggest shift in the landscape ...

a CGM option developed by DexCom for people not using insulin therapy. That includes many patients with type 2 diabetes and even those with pre-diabetes. There's a vast market here. According to ...

The Government of Alberta is expanding its coverage of continuous glucose monitors (CGMs) to eligible adults in an effort to ...

Making headway in this market, in similar populations in other countries, and with prediabetes patients as CGM awareness continues to grow could all allow DexCom's financial results to remain ...

This expansion fulfils a key recommendation from the Diabetes Working Group.